Low HIV-1 transmitted drug resistance in Bulgaria against a background of high clade diversity

被引:17
作者
Alexiev, Ivailo [1 ]
Shankar, Anupama [2 ]
Wensing, A. M. J. [3 ]
Beshkov, Danail [1 ]
Elenkov, Ivaylo [4 ]
Stoycheva, Mariyana [5 ]
Nikolova, Daniela [6 ]
Nikolova, Maria [7 ]
Switzer, William M. [2 ]
机构
[1] Natl Ctr Infect & Parasit Dis, Natl Reference Lab HIV, Sofia, Bulgaria
[2] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA
[3] Univ Med Ctr Utrecht, Virol, Utrecht, Netherlands
[4] Hosp Infect & Parasit Dis, Sofia, Bulgaria
[5] Med Univ, Dept Infect Dis, Plovdiv, Bulgaria
[6] Med Univ, Clin Infect Dis, Varna, Bulgaria
[7] Natl Ctr Infect & Parasit Dis, Natl Reference Lab Immunol, Sofia, Bulgaria
关键词
antiretroviral mutations; surveillance; viral heterogeneity; eastern Europe; MOLECULAR EPIDEMIOLOGY; PREVALENCE; MUTATIONS; SUBTYPES; SURVEILLANCE; INFECTION; STRAINS; NAIVE; SEX; MEN;
D O I
10.1093/jac/dkv011
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: To determine transmitted drug resistance (TDR) and HIV-1 genetic diversity in Bulgaria. Methods: The prevalence of TDR and HIV-1 subtypes was determined in 305/1446 (21.1%) persons newly diagnosed with HIV/AIDS from 1988 to 2011. TDR mutations (TDRMs) in protease and reverse transcriptase were defined using the WHO HIV drug mutation list. Phylogenetic analysis was used to infer polymerase (pol) genotype. Results: TDRMs were found in 16/305 (5.2%) persons, 11 (3.6%) with resistance to NRTIs, 5 (1.6%) with resistance to NNRTIs and 3 (0.9%) with resistance to PIs. Dual-class TDRMs were found in three (1.0%) patients and one statistically supported cluster of TDRMs comprising two individuals with subtype B infection. TDRMs were found in 10 heterosexuals, 4 MSM and two intravenous drug users. Phylogenetic analyses identified high HIV-1 diversity consisting of mostly subtype B (44.6%), subtype C (3.3%), sub-subtype A1 (2.6%), sub-subtype F1 (2.3%), sub-subtype A-like (3.6%), subtype G (0.3%), CRF14_BG (1.6%), CRF05_DF (1.3%), CRF03_AB (0.3%) and unique recombinant forms (1.3%). Conclusions: We found a low prevalence of TDR against a background of high HIV-1 genetic diversity among anti-retroviral-naive patients in Bulgaria. Our results provide baseline data on TDR and support continued surveillance of high-risk populations in Bulgaria to better target treatment and prevention efforts.
引用
收藏
页码:1874 / 1880
页数:7
相关论文
共 27 条
  • [1] HIV-1 subtype distribution and its demographic determinants in newly diagnosed patients in Europe suggest highly compartmentalized epidemics
    Abecasis, Ana B.
    Wensing, Annemarie M. J.
    Paraskevis, Dimitris
    Vercauteren, Jurgen
    Theys, Kristof
    de Vijver, David A. M. C. Van
    Albert, Jan
    Asjo, Birgitta
    Balotta, Claudia
    Beshkov, Danail
    Camacho, Ricardo J.
    Clotet, Bonaventura
    De Gascun, Cillian
    Griskevicius, Algis
    Grossman, Zehava
    Hamouda, Osamah
    Horban, Andrzej
    Kolupajeva, Tatjana
    Korn, Klaus
    Kostrikis, Leon G.
    Kuecherer, Claudia
    Liitsola, Kirsi
    Linka, Marek
    Nielsen, Claus
    Otelea, Dan
    Paredes, Roger
    Poljak, Mario
    Puchhammer-Stoeckl, Elisabeth
    Schmit, Jean-Claude
    Sonnerborg, Anders
    Stanekova, Danika
    Stanojevic, Maja
    Struck, Daniel
    Boucher, Charles A. B.
    Vandamme, Anne-Mieke
    [J]. RETROVIROLOGY, 2013, 10
  • [2] Antoniadou ZA, 2014, AIDS RES HUM RETROV, V30, P225, DOI [10.1089/aid.2013.0166, 10.1089/AID.2013.0166]
  • [3] Drug Resistance Mutations for Surveillance of Transmitted HIV-1 Drug-Resistance: 2009 Update
    Bennett, Diane E.
    Camacho, Ricardo J.
    Otelea, Dan
    Kuritzkes, Daniel R.
    Fleury, Herve
    Kiuchi, Mark
    Heneine, Walid
    Kantor, Rami
    Jordan, Michael R.
    Schapiro, Jonathan M.
    Vandamme, Anne-Mieke
    Sandstrom, Paul
    Boucher, Charles A. B.
    van de Vijver, David
    Rhee, Soo-Yon
    Liu, Tommy F.
    Pillay, Deenan
    Shafer, Robert W.
    [J]. PLOS ONE, 2009, 4 (03):
  • [4] The emerging and re-emerging human immunodeficiency virus epidemics in Europe
    Bozicevic, I.
    Handanagic, S.
    Lepej, S. Z.
    Begovac, J.
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2013, 19 (10) : 917 - 929
  • [5] DHHS Panel, 2013, GUID US ANT AG HIV 1
  • [6] Drummond AJ, 2005, MOL BIOL EVOL, V22, P1185, DOI [10.1093/molbev/msi103, 10.1093/molbev/mss075]
  • [7] Grgic I, 2013, AIDS RES HUM RETROV, V29, P329, DOI [10.1089/aid.2012.0191, 10.1089/AID.2012.0191]
  • [8] Antiretroviral drug resistance testing in adult HIV-1 infection:: 2008 recommendations of an International AIDS Society-USA panel
    Hirsch, Martin S.
    Guenthard, Huldrych F.
    Schapiro, Jonathan M.
    Brun-Vezinet, Francoise
    Clotet, Bonaventura
    Hammer, Scott M.
    Johnson, Victoria A.
    Kuritzkes, Daniel R.
    Mellors, John W.
    Pillay, Deenan
    Yeni, Patrick G.
    Jacobsen, Donna M.
    Richman, Douglas D.
    [J]. CLINICAL INFECTIOUS DISEASES, 2008, 47 (02) : 266 - 285
  • [9] Detailed Molecular Epidemiologic Characterization of HIV-1 Infection in Bulgaria Reveals Broad Diversity and Evolving Phylodynamics
    Ivanov, Ivailo Alexiev
    Beshkov, Danail
    Shankar, Anupama
    Hanson, Debra L.
    Paraskevis, Dimitrios
    Georgieva, Viara
    Karamacheva, Lyudmila
    Taskov, Hristo
    Varleva, Tonka
    Elenkov, Ivaylo
    Stoicheva, Mariana
    Nikolova, Daniela
    Switzer, William M.
    [J]. PLOS ONE, 2013, 8 (03):
  • [10] An AB recombinant and its parental HIV type 1 strains in the area of the former Soviet Union: low requirements for sequence identity in recombination
    Liitsola, K
    Holm, K
    Bobkov, A
    Pokrovsky, V
    Smolskaya, T
    Leinikki, P
    Osmanov, S
    Salminen, M
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 2000, 16 (11) : 1047 - 1053